# A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants

> **NCT06504043** · PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Hasten Biopharmaceutical Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Hypercholesterolemia
- Healthy Volunteers
- LDL-Cholesterol

## Interventions

- **DRUG:** HST101

## Key facts

- **NCT ID:** NCT06504043
- **Lead sponsor:** Hasten Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-09-17
- **Primary completion:** 2025-01-08
- **Final completion:** 2025-03-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06504043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06504043, "A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06504043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*